Residency · Residency · Vascular Surgery

Infrainguinal Bypass: Indications, Conduit Selection, and Technique

Overview

Infrainguinal bypass is a fundamental open vascular procedure used to restore blood flow to the lower extremities by bypassing occlusive disease from the common femoral artery to a target vessel in the leg or foot. It remains the gold standard for durable revascularization in patients with critical limb-threatening ischemia (CLTI), especially in cases involving complex disease patterns. The BEST-CLI trial published in 2022 confirmed that surgical bypass using an adequate single-segment great saphenous vein (ssGSV) offers superior outcomes compared to endovascular interventions for CLTI.

Indications

The primary indication for infrainguinal bypass is critical limb-threatening ischemia, which includes rest pain classified as Rutherford category 4, minor tissue loss (Rutherford 5), and major tissue loss (Rutherford 6). It is also indicated for lifestyle-limiting claudication that is refractory to medical therapy and exercise, particularly when the patient's anatomy is unsuitable for or has failed endovascular intervention. Selected cases of acute limb ischemia may benefit from bypass combined with thrombectomy. Additionally, infrainguinal bypass can be used to exclude popliteal artery aneurysms by creating a bypass around the aneurysm.

Preoperative Assessment

Patient Evaluation

A thorough cardiac risk assessment following ACC/AHA guidelines is crucial, as cardiac status is the most important predictor of perioperative mortality. Evaluating the patient's functional status and life expectancy is essential, with bypass surgery being most beneficial when life expectancy exceeds two years. Ambulatory status and rehabilitation potential should also be assessed, along with renal function to plan for contrast exposure during imaging studies.

Vascular Assessment

The vascular evaluation begins with a pulse examination and measurement of ankle-brachial and toe-brachial indices (ABI/TBI). Imaging with arterial duplex ultrasound or computed tomography angiography (CTA) or magnetic resonance angiography (MRA) is used to define the inflow, outflow, and target vessels. Preoperative vein mapping with duplex ultrasound is mandatory to assess the diameter (preferably greater than 3 mm), continuity, and quality of the great saphenous vein (GSV). If the GSV is unavailable or inadequate, alternative conduits must be mapped.

Target Vessel Selection

The most proximal target vessel with continuous runoff to the foot should be selected. While angiosome-directed revascularization—targeting the artery supplying the area of tissue loss—may improve wound healing, this remains controversial. Ideally, at least one tibial vessel with pedal runoff is required to ensure adequate distal perfusion.

<image>Preoperative duplex ultrasound vein mapping of the great saphenous vein showing diameter measurements at multiple levels from the saphenofemoral junction to the ankle, with markings on the skin for surgical planning</image>

Conduit Selection

Autogenous Vein (Preferred)

The single-segment great saphenous vein (ssGSV) is the best conduit for infrainguinal bypass, offering the highest long-term patency rates. The BEST-CLI trial demonstrated that ssGSV bypasses had superior outcomes in terms of major adverse limb events and all-cause mortality compared to endovascular therapy. Five-year primary patency rates range from 60 to 70%, with secondary patency reaching 75 to 85%. The vein can be used in either a reversed or in-situ configuration.

When the ssGSV is unavailable, alternative autogenous conduits include the contralateral GSV, which is the next best option. The small saphenous vein (SSV) may be adequate for short bypasses. Arm veins such as the cephalic and basilic veins can also be used, although they have a smaller caliber and are more prone to aneurysmal degeneration. These can be employed as single segments or as composite/spliced grafts, which join multiple vein segments. While composite vein grafts have inferior patency compared to ssGSV, they still outperform prosthetic grafts.

Prosthetic Conduit

Polytetrafluoroethylene (PTFE) is the most commonly used prosthetic conduit, with Dacron being less frequently used for infrainguinal bypasses. Prosthetic grafts are acceptable for above-knee femoropopliteal bypasses when autogenous vein is unavailable, with five-year patency rates of 40 to 60%. However, prosthetic grafts yield poor results for below-knee and tibial targets, with five-year patency rates of only 20 to 30%.

Surgical Technique

Reversed Vein Bypass

In the reversed vein bypass technique, the GSV is harvested and reversed to allow valve-free antegrade blood flow. The proximal anastomosis is performed end-to-side on the common femoral artery, and the distal anastomosis is end-to-side on the target artery. This method simplifies valve management but can result in size mismatch because the vein is larger proximally and smaller distally, which is the opposite of the ideal configuration.

In-Situ Vein Bypass

In the in-situ bypass, the GSV is left in its native bed, and the valves are lysed using a valvulotome to permit forward flow. Tributaries are ligated or clipped to prevent arteriovenous fistulae. This technique offers better size matching between the vein and target artery, preserves the vasa vasorum, and involves less vein handling. However, it is technically more complex and carries the risk of missed tributaries leading to AV fistulae or retained valves causing flow obstruction. Intraoperative completion angioscopy or angiography is used to identify and address these issues.

Key Technical Points

Before performing the bypass, it is essential to confirm adequate inflow and address any proximal disease. The graft can be tunneled anatomically along the course of native vessels or subcutaneously. Anastomoses are constructed using 6-0 or 7-0 polypropylene sutures, often employing a parachute technique for small vessels. Completion imaging with duplex ultrasound, angiography, or angioscopy is mandatory to detect technical defects such as intimal flaps, retained valves, stenosis, or AV fistulae. Systemic heparinization is administered before clamping, targeting an activated clotting time (ACT) greater than 250 seconds.

<image>Surgical diagram comparing reversed saphenous vein bypass and in-situ saphenous vein bypass configurations, showing valve orientation, flow direction, and tributary management in each technique</image>

Bypass Configurations

Femoral-to-Popliteal (Above-Knee)

This configuration targets the above-knee popliteal artery and achieves the best results when using vein grafts, although prosthetic grafts are acceptable. Five-year patency rates for vein grafts in this location range from 70 to 80%.

Femoral-to-Popliteal (Below-Knee)

Targeting the below-knee popliteal artery (P3 segment), this bypass strongly favors the use of vein conduits. Five-year patency rates with vein grafts are approximately 65 to 75%.

Femoral-to-Tibial/Pedal

This configuration targets the anterior tibial, posterior tibial, peroneal, or dorsalis pedis arteries. Use of an autogenous vein conduit is mandatory to achieve acceptable outcomes, with five-year patency rates between 55 and 65%. Pedal bypasses, pioneered by LoGerfo, demonstrate that even very distal targets can provide effective limb salvage.

Graft Surveillance

Duplex ultrasound surveillance is essential to maintain vein graft longevity. The recommended schedule includes examinations at 1 month, 3 months, 6 months, and then every 6 to 12 months thereafter. Key parameters to monitor include peak systolic velocity (PSV) greater than 300 cm/s, which suggests stenosis, and a PSV ratio exceeding 3.5 across a lesion, indicating significant stenosis. A mid-graft velocity below 45 cm/s suggests impending graft failure. Detected stenoses should be promptly revised, either by open patch or jump graft procedures or by endovascular balloon angioplasty. With surveillance and timely intervention, assisted primary patency rates can reach 80 to 90% at five years.

Complications

Wound complications are the most common adverse events, occurring in 10 to 20% of cases, especially in the groin region. Graft thrombosis can occur early (within 30 days), usually due to technical issues, or late, often caused by intimal hyperplasia or progression of disease. Graft infection, although less common (1 to 5%), is a devastating complication that typically requires graft excision. Myocardial infarction remains the leading cause of perioperative death. Compartment syndrome may develop following prolonged ischemia and reperfusion injury.

<image>Algorithm for management of infrainguinal vein graft stenosis detected on duplex surveillance, showing decision points based on velocity criteria, stenosis severity, and intervention options including open revision and endovascular angioplasty</image>

Clinical Pearls

The most successful bypasses are performed using the best conduit to the best target vessel; compromising on conduit quality should be avoided if alternatives exist. Preoperative vein mapping is essential, as patients lacking adequate autogenous vein represent a different surgical challenge. In-situ bypass requires meticulous identification and ligation of all tributaries to prevent steal phenomena. Completion imaging is non-negotiable because technical errors during surgery are the most common cause of early graft failure. Maintaining a low threshold for graft surveillance is critical, as the ability to revise a failing graft before thrombosis is the primary advantage of surveillance. For patients with CLTI, vein bypass has been demonstrated to be superior to endovascular therapy when an adequate ssGSV is available, as confirmed by the BEST-CLI trial.

References

• Conte MS, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities. J Vasc Surg. 2015;61(3S):2S-41S.
• Farber A, et al. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia (BEST-CLI). N Engl J Med. 2022;387:2305-2316.
• Bradbury AW, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial. J Vasc Surg. 2010;51(5S):5S-17S.
• Shah DM, et al. Long-term results of in situ saphenous vein bypass. Ann Surg. 1995;222(4):438-448.
• Mills JL, et al. The Society for Vascular Surgery lower extremity threatened limb classification system. J Vasc Surg. 2014;59(1):220-234.

Read this lecture as Markdown